πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 406 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10294274

Polypeptide ligands specific for plasma kallikrein

BicycleRD Limited Β· Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10294474

Targeting ligands

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue May 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10280197

Discovery of the first selective C5A receptor 2 (C5L2/C5AR2) ligands

The Regents of the University of California Β· Granted Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10266565

Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10266579

Synthetic somatostatin receptor ligands

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10261094

Competitive ligand binding assay for detecting neutralizing antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10246709

Targeting ligands for therapeutic compounds

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10150788

Prodrug compounds and uses thereof

Ligand Pharmaceuticals Incorporated Β· Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10117878

Ligands for nematode nuclear receptors and uses thereof

The Board of Regents of the University of Texas System Β· Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10118942

Toll-like receptor 2 ligands and methods of making and using thereof

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10111859

Methods and compositions associated with the granulocyte colony-stimulating factor recepto

Ligand Pharmaceuticals Incorporated Β· Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10106500

Selective androgen receptor modulators (SARMs) and uses thereof

Ligand Pharmaceuticals Incorporated Β· Granted Tue Oct 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10100083

Leukemia stem cell targeting ligands and methods of use

The Regents of the University of California Β· Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10088485

Methods of screening compounds that can modulate NR2F6 by displacement of a reference liga

Regen Biopharma, Inc. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10030034

Heterocycle amines and uses thereof

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10000522

Derivatives of uridine 5β€²-cyclophosphate useful to treat hepatitis C viral infections

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9994817

Use of ligands for the programmed cell death receptor conjugated to solid supports for cul

Northwestern University Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9994600

Prodrug compounds and uses therof

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9993461

Method for treating disorders associated with glomerular function

Ligand Pharmaceuticals Incorporated Β· Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9962449

MultiLigand agent for drug delivery

ARCTURUS THERAPEUTICS, INC. Β· Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9962370

Methods of treatment associated with the granulocyte colony-stimulating factor receptor

Ligand Pharmaceuticals Incorporated Β· Granted Tue May 08 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9895448

Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic

ARBUTUS BIOPHARMA CORPORATION Β· Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9884070

Selective high-affinity polydentate ligands and methods of making such

The Regents of the University of California Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9731011

Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and int

EnGeneIC Molecular Delivery Pty Ltd Β· Granted Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted